Tumor immunity is an extremely complex biological process, and factors affecting the efficacy of immune checkpoint inhibitors (IMCIs) are associated with PD-L1 expression level, tumor-infiltrating lymphocytes (TILs), and tumor mutational burden (TMB) [13]. The gene discussed is CD274; the disease is neoplasm.